MYC and pancreatic ductal adenocarcinoma: Our GSEA results [Figure 5A], together with the observed downregulation of MHC-I pathway genes [Figure 4B], suggest that MYC activation contributes to an immunosuppressive TME where a high neoantigen load becomes biologically irrelevant, mirroring MYC-driven immune evasion reported in pancreatic ductal adenocarcinoma (PDAC)[31] and hepatocellular carcinoma (HCC)[32].